Related Experiment Video
Updated: Jun 19, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Clinico-pathological features and outcomes in chronic phase chronic myeloid leukemia patients treated with
Syed Muhammad Irfan1, Yasmin Bhurgri
1Liaquat National Hospital and Medical College, Karachi, Pakistan.
Insights
Hydroxyurea treatment for chronic myeloid leukemia (CML) in chronic phase showed outcomes comparable to published data. However, CML was diagnosed in a younger population with significant delays.
Area of Science:
- Hematology
- Oncology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Hydroxyurea is a chemotherapy agent used in CML management.
Purpose of the Study:
- To investigate the clinico-pathological characteristics and outcomes of chronic phase CML patients treated with hydroxyurea.
- To compare these findings with existing literature.
Main Methods:
- A single-center study conducted from January 1997 to June 2003.
- Data collected retrospectively from patient records.
- Diagnosis based on clinical findings, complete blood counts, leukocyte alkaline phosphatase (LAP) scores, and genetic studies (Philadelphia chromosome, bcr-abl transcripts).
- Treatment administered via hydroxyurea (30-50 mg/kg/day).
Main Results:
- 176 patients (104 male, 72 female) were analyzed, with a median age of 39 years.
- Significant delay in diagnosis (median 156 days) was noted.
- 81% of patients were alive at study's end; 43.2% experienced disease advancement, including transformation to acute leukemia in 20%.
- Disease progression was the primary cause of mortality (16.4%).
Conclusions:
- CML in this cohort presented at a younger age with delayed diagnosis.
- The clinico-pathological features and outcomes observed were similar to those reported in other studies.
- Hydroxyurea demonstrated comparable efficacy in managing chronic phase CML within this patient group.
Objective:
To study the clinico-pathological features and major outcomes in patients with chronic myeloid leukemia, chronic phase, treated with hydroxyurea.
Methods:
This is a single centre study extending from January 1997 to June 2003. Data were retrieved from the patients' records on predetermined performance and analyzed. Patients were primarily diagnosed on the basis of clinical findings, complete blood counts and leukocyte alkaline phosphate (LAP) scores. Bone marrow/trephine and genetic studies were conducted where appropriate. Patients were primarily treated with capsule hydroxyurea 30-50/ kg/day.
Results:
One hundred and seventy six patients, 104 (59%) male and 72 (41%) females were included in the study. The median age at diagnosis was 39 years (range 11 to 66 years). The median delay in diagnosis was 156 days (range 30 to 360 days). Eighty four patients (47.7%) presented with pain/discomfort in the left hypochondrium. The mean hemoglobin, white blood cell count and platelet counts were 10.3 g/dl, 141,000/UL and 341,000/UL respectively associated with a low LAP score. Hyper-leucocytosis was observed in 19 (10.7%) cases. LDH values above 1,000 ug/l were observed in 38 (21.5%) cases and creatinine above 1.5 ug/l in 21 (12%) cases. All patients tested, were positive for Philadelphia chromosome and bcr-abl transcripts. At the close of the study, disease advancement was observed in 76 (43.2%) cases, of which 35 (20%) transformed to acute leukemia. One hundred and forty three patients (81%) were alive at the close of the study. One hundred and two (58.4%) patients were in chronic phase, 22 (12.5%) in accelerated phase and 19 (10.7%) in blast crisis. Disease progression remained the major cause of death and was seen in 29 (16.4%) patients.
Conclusion:
In the study population, CML was observed in a younger age group with significant delay in definitive diagnosis. Clinico-pathological features and major outcomes, however, appear comparable to published data.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:29Acute Kidney Injury III: Clinical Manifestations